FDA approves Obecure's obesity drug

Obesity-drug startup Obecure, which is part of the Biolight group has received FDA approval for starting Phase 2 clinical trials of OBE 101, its drug for weight control on human beings.

By SHARON WROBEL
September 5, 2006 09:19

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later

Obesity-drug startup Obecure, which is part of the Biolight group has received FDA approval for starting Phase 2 clinical trials of OBE 101, its drug for weight control on human beings. Obecure is already in contact with 20 medical centers in the U.S. to run the trials and to begin giving patients its drug. The first trials are expected to start the coming January to avoid the Christmas holidays, a period in which people tend to put on weight.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS